Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Administrative · Pharmacy · NJ · Orthopedics, Rheumatology, Pain Management +1 moreLow impact

MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)

Effective date
Apr 1, 2026
Identified
Jun 19, 2026

Summary

This is a routine annual reissue of the Independence Blue Cross Medicare Advantage policy for Zilretta (Triamcinolone Acetonide ER Injectable) with no substantive changes to coverage criteria, medical necessity requirements, or billing codes. The policy continues to cover Zilretta for knee osteoarthritis when specific clinical criteria are met, and repeat injections remain non-covered/experimental.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01No immediate action required.
02This is a reissue with no changes to coverage policy, billing codes, or requirements.
03Billing team should verify that current claim submission practices for HCPCS J3304 (Zilretta) already include verification of: (1) patient age 18+, (2) knee osteoarthritis diagnosis, (3) no prior Zilretta treatment, (4) documented failure of conservative therapy, (5) documented NSAID/tramadol trial failure, and (6) documented prior intra-articular steroid injection failure.
04Continue to deny any claims for repeat Zilretta injections to the same knee, as these remain experimental/investigational.
05File claims only for Independence Blue Cross Medicare Advantage members in New Jersey.

Codes mentioned

J3304M17.0M17.10M17.11M17.12M17.2M17.30M17.31M17.32M17.4M17.5

Original notice

MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)LowNo effective date · PharmacyMA05.070, Apos® biomechanical shoe systemLowEffective Jan 1, 2024 · Pharmacy05.00.84, Apos® biomechanical shoe systemLowEffective Jan 1, 2024 · Pharmacy11.14.07y, Intra-Articular Injection of Hyaluronan for the Treatment of OsteoarthritisHighEffective Dec 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNJ policy changesOrthopedicsRheumatologyPain ManagementSports MedicineCode J3304Code M17.0Code M17.10Code M17.11Code M17.12Code M17.2Code M17.30Code M17.31Code M17.32Code M17.4Code M17.5

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account